Neemat M Kassem, Sahar Sharaf, Ahmed Abdel Aziz , Mona Mohsen, Hebatallah AKassem, Sara El Khateeb, Nashwa Medhat, Basant Nagdy, Rabab Abdel Moneim and Mohammed Abdulla
Cairo University, Egypt
Posters & Accepted Abstracts: Arch Cancer Res
Background: Colorectal cancer (CRC) has been identified as the third most common cancer worldwide. Gene mutation and defective cell regulation are important processes in the development of CRC. Assessment of genetic mutations is an essential element in the modern era of personalized cancer treatment.
Purpose: We performed a pilot study identifying the frequencies of genetic changes in six frequently mutated genes: KRAS, NRAS, BRAF, PIK3CA, PTEN and TP53 in Egyptian CRC patients. The secondary objective was to validate the next-generation sequencing (NGS) technology and to develop a workflow process in the clinical setting.
Methodology: This study investigated the mutations in these 6 genes using targeted NGS. The study included 14 archived Formalin-fixed paraffin-embedded (FFPE) tumor specimens in addition to 11 external quality controls (EQC).
Results: The median age of CRC patients was 60.5 years, 21.4% of patients were ≤40 years old, females 57.1% and males 42.9% with M/F ratio 0.75:1. The mutation frequencies of KRAS, BRAF, PIK3CA, PTEN and TP53 genes in Egyptian CRC patients were 35.7%, 14.3%, 21.4%, 7.1% and 71.4% respectively, with no mutations detected in NRAS gene which may be due to the limited study population.
Conclusion: Technical validity and clinical efficacy are the two major arguments in the analysis of NGS data. The major benefit of NGS in comparison to more traditional methods is its ability to study multiple genes at once. Implementation of targeted NGS in clinical settings allows for a trustworthy description of the most common mutations, which can direct therapeutic decisions for CRC patients.
E-mail:
nkkassem@hotmail.com
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 